Publication date: 04/10/2017
ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has attracted Capricorn Venture Partners to conclude the second closing of its series A financing round, raising another 1.5 million euro. The financing will be used to further develop and launch its veterinary product portfolio.
ViroVet pioneers in developing novel and innovative veterinary vaccines based on a unique proprietary technology platform developed at the Rega Institute for Medical Research of KU Leuven that has the potential to produce vaccines faster and more cost-effectively. These vaccines are tailormade to maximize efficacy and minimize safety concerns. In addition, the vaccines are thermostable thereby removing any cold-chain requirement. Earlier this year, ViroVet and GALVmed entered into a collaboration to develop novel vaccines for sheep and goats.
The company also develops fast-acting antiviral drugs that are critical to the effective control and treatment of respiratory diseases of cattle and swine, thereby reducing secondary bacterial infections and the associated use of antibiotics.
Erwin Blomsma, PhD, co-founder and CEO of ViroVet stated that “We are excited that Capricorn Venture Partners came on board. With the second closing of our series A investment round, we are able to reach important milestones and to show the animal health sector that there are better ways to treat as well as prevent viral diseases in livestock.”
Ludwig Goris, Investment Manager at Capricorn Venture Partners added: “We are very excited to announce ViroVet as the first investment out of our Capricorn Sustainable Chemistry Fund. We have been following the company for some time and believe strongly in the disruptive market potential of its innovative anti-viral and vaccine technology. We are convinced that the team of Erwin, Nesya, Stefaan and their colleagues will be very successful and are happy to join a strong consortium of investors.”
ViroVet is a biopharmaceutical company with a clear objective to develop innovative technologies to improve the health and value of livestock. The company is headquartered in Heverlee near Leuven, Belgium and continues to build on the livestock assets and know-how that it has accumulated since 2008 while adding new products, including vaccines, to the pipeline. PMV (via Biotech Fund Flanders), Agri Investment Fund, Gemma Frisius Fund, Vives Louvain Technology Fund and Capricorn Sustainable Chemistry Fund participated in ViroVet’s series A round.
Capricorn Venture Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Venture Partners is managing the venture capital funds Capricorn Sustainable Chemistry Fund, Capricorn ICT Fund, Capricorn Health-tech Fund and Capricorn Cleantech Fund. In addition, it is the management company of Quest for Growth, quoted on NYSE Euronext Brussels, and the investment manager of Quest Cleantech Fund, sub-fund of Quest Management SICAV (www.capricorn.be).